Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Essential fructosuria is a rare autosomal recessive disorder of fructose metabolism caused by a deficiency of fructokinaseenzyme activity. It is characterized by elevated fructosemia and presence of fructosuria following ingestion of fructose and related sugars (sucrose, sorbitol). Essential fructosuria is clinically asymptomatic and harmless. Dietary restriction is not indicated.
Features include always present findings: Impairment of fructose metabolism, Elevated urine fructose level, and Abnormal circulating enzyme concentration or activity; and very common findings: Abnormality of glycolipid metabolism, Abnormal erythrocyte enzyme concentration or activity, and Abnormal urine carbohydrate level.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Metabolism | 2 | Impairment of fructose metabolism, Abnormality of glycolipid metabolism |
KHK encodes ketohexokinase (298 aa). Catalyzes the phosphorylation of the ketose sugar fructose to fructose-1-phosphate Highest expression in Liver (118.1 TPM) and Kidney Cortex (54.2 TPM).
Essential fructosuria is associated with mutations in the KHK gene on chromosome 2.
The KHK protein participates in Essential fructosuria pathway.
KHK is classified as a druggable target (Druggable Genome, Enzyme, and Kinase categories) with score 52.2.
Genetic testing for KHK is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for essential fructosuria has been reported in the published literature.
Phenotype severity distribution: 3 always present features, 3 very common features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for essential fructosuria.
4 publications have been identified in PubMed for essential fructosuria. Research spans Review / Meta-Analysis (50%), Diagnostic / Biomarker (25%), and Case Report / Case Series (25%).
Mathew D (2025). [PMID: 40789968](https://pubmed.ncbi.nlm.nih.gov/40789968/). *Compr Physiol*. [Review / Meta-Analysis]
Almoghrabi YM (2025). [PMID: 40626223](https://pubmed.ncbi.nlm.nih.gov/40626223/). *Front Nutr*. [Review / Meta-Analysis]
Elsaman T (2025). [PMID: 40260383](https://pubmed.ncbi.nlm.nih.gov/40260383/). *Front Pharmacol*. [Diagnostic / Biomarker]
Zawadzki J (2025). [PMID: 40428357](https://pubmed.ncbi.nlm.nih.gov/40428357/). *Genes (Basel)*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 7:12 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center